Myelodysplastic Syndromes
7 videos · last 6 months shuffled daily, then older videos newest first
▶
35:12 Thrombosomes for Severe Bleeding in Leukemia and MDS
Dr. Maro Ohanian of MD Anderson Cancer Center discusses the development of thrombosomes, a freeze-dried platelet-derived product, and a phase 2 randomised trial comparing them with standard platelets in patients with MDS and acute leukemia, for OncoDaily.
▶
11:35 SOHO 2026 Highlights in Lymphoma, MDS and CLL
Jasmine M. Zain, MD, of Memorial Sloan Kettering, David Sallman, MD, of Moffitt Cancer Center, and Julie M. Vose, MD, of the University of Nebraska Medical Center discuss SOHO 2026 presentations, including phase 2a ofirnoflast results in lower-risk MDS.
▶
9:33 Racial and Ethnic Diversity in Parkinson's Drug Trials
Dr. Farley Reis Rodrigues and Dr. Daniel Di Luca present their systematic review of racial and ethnic diversity in trials of disease-modifying drugs for Parkinson's disease, for the International Parkinson and Movement Disorder Society.
▶
2:32 Fedratinib Demonstrates Favorable OS in MDS/MPN Overlap Syndrome
Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses final analysis data from a phase 2 study that evaluated fedratinib in myelodysplastic syndromes/myeloproliferative neoplasms overlap syndrome.
▶
45:09 Rapid Genomic Profiling for the MyeloMATCH Trial
Cecilia Yeung describes a rapid genomic characterization workflow built for the MyeloMATCH umbrella trial, which assigns AML and MDS participants to molecularly defined substudies.
▶
1:38 Key Highlights from the Phase 1 Dose Escalation Study of PRGN-3006 UltraCAR-T Presented At
Dr. David A. Sallman of Moffitt Cancer Center discusses highlights from the Phase 1/1b safety study of PRGN-3006 UltraCAR-T in relapsed or refractory CD33-positive acute myeloid leukemia and higher-risk myelodysplastic syndromes.
▶
3:49 How Are MDS Clinical Trials Carried out? What Should I Expect?
Dr. Amy DeZern, a hematologist and oncologist, explains the types of clinical trials in MDS and what to expect from taking part in an interventional trial.